{"pmid":32427188,"pmcid":"PMC7232065","title":"Better the drug you know: Commentary on \"Daughton 2020, Natural experiment concept to accelerate the re-purposing of existing therapeutics for Covid-19\".","text":["Better the drug you know: Commentary on \"Daughton 2020, Natural experiment concept to accelerate the re-purposing of existing therapeutics for Covid-19\".","Glob Epidemiol","Broadbent, Alex","32427188"],"journal":"Glob Epidemiol","authors":["Broadbent, Alex"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32427188","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.gloepi.2020.100027","topics":["Treatment"],"weight":1,"_version_":1667352728774377472,"score":9.490897,"similar":[{"pmid":32501449,"pmcid":"PMC7241324","title":"Response to: Broadbent 2020, Better the drug you know: Commentary on \"Daughton 2020, Natural experiment concept to accelerate the re-purposing of existing therapeutics for Covid-19\".","text":["Response to: Broadbent 2020, Better the drug you know: Commentary on \"Daughton 2020, Natural experiment concept to accelerate the re-purposing of existing therapeutics for Covid-19\".","Glob Epidemiol","Daughton, Christian G","32501449"],"journal":"Glob Epidemiol","authors":["Daughton, Christian G"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32501449","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.gloepi.2020.100028","locations":["Daughton"],"weight":0,"_version_":1668890966365306880,"score":157.88432},{"pmid":32427166,"pmcid":"PMC7227507","title":"Natural experiment concept to accelerate the Re-purposing of existing therapeutics for Covid-19.","text":["Natural experiment concept to accelerate the Re-purposing of existing therapeutics for Covid-19.","One of the many questions with respect to controlling the novel coronavirus pandemic is whether existing drugs can be re-purposed (re-positioned) for the prevention or treatment of Covid-19 - or for any future epidemic. The usefulness of existing approaches for re-purposing range from computational modeling to clinical trials. These are often time-consuming, resource intensive, and prone to failure. Proposed here is a new but simple concept that would capitalize on the opportunity presented by the on-going natural experiment involving the collection of data from epidemiological surveillance screening and diagnostic testing for clinical treatment. The objective would be to also collect for each Covid-19 case the patient's prior usage of existing therapeutic drugs. These drug usage data would be collected for several major test groups - those who test positive for active SARS-CoV-2 infection (using molecular methods) and those who test negative for current infection but also test positive for past infection (using serologic antibody tests). Patients from each of these groups would also be categorized with respect to where they resided on the spectrum of morbidities (from no or mild symptomology to severe). By comparing the distribution of normalized usage data for each drug within each group, drugs that are more associated with particular test groups could be revealed as having potential prophylactic, therapeutic, or contraindicated effects with respect to disease progression. These drugs could then be selected as candidates for further evaluation in fighting Covid-19. Also summarized are some of the numerous attributes, advantages, and limitations of the proposed concept, all pointing to the need for further discussion and evaluation.","Glob Epidemiol","Daughton, Christian G","32427166"],"abstract":["One of the many questions with respect to controlling the novel coronavirus pandemic is whether existing drugs can be re-purposed (re-positioned) for the prevention or treatment of Covid-19 - or for any future epidemic. The usefulness of existing approaches for re-purposing range from computational modeling to clinical trials. These are often time-consuming, resource intensive, and prone to failure. Proposed here is a new but simple concept that would capitalize on the opportunity presented by the on-going natural experiment involving the collection of data from epidemiological surveillance screening and diagnostic testing for clinical treatment. The objective would be to also collect for each Covid-19 case the patient's prior usage of existing therapeutic drugs. These drug usage data would be collected for several major test groups - those who test positive for active SARS-CoV-2 infection (using molecular methods) and those who test negative for current infection but also test positive for past infection (using serologic antibody tests). Patients from each of these groups would also be categorized with respect to where they resided on the spectrum of morbidities (from no or mild symptomology to severe). By comparing the distribution of normalized usage data for each drug within each group, drugs that are more associated with particular test groups could be revealed as having potential prophylactic, therapeutic, or contraindicated effects with respect to disease progression. These drugs could then be selected as candidates for further evaluation in fighting Covid-19. Also summarized are some of the numerous attributes, advantages, and limitations of the proposed concept, all pointing to the need for further discussion and evaluation."],"journal":"Glob Epidemiol","authors":["Daughton, Christian G"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32427166","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.gloepi.2020.100026","topics":["Treatment"],"weight":1,"_version_":1667352728742920192,"score":133.30621},{"pmid":32419524,"title":"Old and re-purposed drugs for the treatment of COVID-19.","text":["Old and re-purposed drugs for the treatment of COVID-19.","Introduction: The coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has developed since December 2019. It has caused a global pandemic with more than three hundred thousand case fatalities. However, apart from supportive care by respirators, no standard medical therapy is validated.Areas covered: This paper presents old drugs with potential in vitro efficacy against SARS-CoV-2. The in vitro database, adverse effects, and potential toxicities of these drugs are reviewed regarding their feasibility of clinical prescription for the treatment of patients with COVID-19. To obtain convincing recommendations, we referred to opinions from the US National Institute of Health regarding drugs repurposed for COVID-19 therapy.Expert opinion: Although strong evidence of well-designed randomized controlled studies regarding COVID-19 therapy is presently lacking, remdesivir, teicoplanin, hydroxychloroquine (not in combination with azithromycin), and ivermectin might be effective antiviral drugs and are deemed promising candidates for controlling SARS-CoV-2. In addition, tocilizumab might be considered as the supplementary treatment for COVID-19 patients with cytokine release syndrome. In future, clinical trials regarding a combination of potentially effective drugs against SARS-CoV-2 need to be conducted to establish the optimal regimen for the treatment of patients with moderate-to-severe COVID-19.","Expert Rev Anti Infect Ther","Jean, Shio-Shin","Hsueh, Po-Ren","32419524"],"abstract":["Introduction: The coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has developed since December 2019. It has caused a global pandemic with more than three hundred thousand case fatalities. However, apart from supportive care by respirators, no standard medical therapy is validated.Areas covered: This paper presents old drugs with potential in vitro efficacy against SARS-CoV-2. The in vitro database, adverse effects, and potential toxicities of these drugs are reviewed regarding their feasibility of clinical prescription for the treatment of patients with COVID-19. To obtain convincing recommendations, we referred to opinions from the US National Institute of Health regarding drugs repurposed for COVID-19 therapy.Expert opinion: Although strong evidence of well-designed randomized controlled studies regarding COVID-19 therapy is presently lacking, remdesivir, teicoplanin, hydroxychloroquine (not in combination with azithromycin), and ivermectin might be effective antiviral drugs and are deemed promising candidates for controlling SARS-CoV-2. In addition, tocilizumab might be considered as the supplementary treatment for COVID-19 patients with cytokine release syndrome. In future, clinical trials regarding a combination of potentially effective drugs against SARS-CoV-2 need to be conducted to establish the optimal regimen for the treatment of patients with moderate-to-severe COVID-19."],"journal":"Expert Rev Anti Infect Ther","authors":["Jean, Shio-Shin","Hsueh, Po-Ren"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32419524","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1080/14787210.2020.1771181","keywords":["covid-19","favipiravir","remdesivir","sars-cov-2","re-purposed"],"locations":["optimal"],"e_drugs":["Hydroxychloroquine","Azithromycin","Ivermectin","Teicoplanin","tocilizumab","remdesivir"],"topics":["Treatment"],"weight":1,"_version_":1667254896711172096,"score":55.15058},{"pmid":32353743,"pmcid":"PMC7179490","title":"Purposing Saikosaponins for the treatment of COVID-19.","text":["Purposing Saikosaponins for the treatment of COVID-19.","Med Hypotheses","Bahbah, Eshak I","Negida, Ahmed","Nabet, Mohamed Salah","32353743"],"journal":"Med Hypotheses","authors":["Bahbah, Eshak I","Negida, Ahmed","Nabet, Mohamed Salah"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32353743","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.mehy.2020.109782","e_drugs":["saikosaponin"],"topics":["Treatment"],"weight":1,"_version_":1666138495585878016,"score":42.00184}]}